OctoPlus signs drug delivery agreement with Novartis

Published: 1-Jul-2010
Research & Development Finance

PolyActive technology to be used to develop controlled release formulation of undisclosed compound


OctoPlus, a Dutch drug delivery company, has signed an agreement with Novartis relating to the use of OctoPlus' controlled release technology.

Under the contract, OctoPlus will develop, up to in vivo feasibility, a controlled release formulation of an undisclosed compound using its PolyActive proprietary drug delivery technology. Novartis will fully reimburse OctoPlus for its activities under the agreement. Further financial terms of the agreement were not disclosed.

Simon Sturge, ceo of OctoPlus, said: ‘I am delighted to see our technology being evaluated by such a prestigious company as Novartis. This along with the recent data on Locteron in more than 175 patients continues to build the strong support behind our PolyActive controlled release technology and our capabilities in this area.’

  • Companies:
  • OctoPlus
  • Novartis
See more

You may also like

Research & Development

Novartis' Leqvio demonstrates LDL cholesterol management potential in Phase III trial

Read more
The siRNA can significantly reduce the levels of LDL cholesterol in the blood, reducing the risk of ASCVD in patients

Trending Articles

  1. How flow chemistry is transforming drug discovery New Syrris eBook explores techniques driving efficiency and innovation
  2. Transmission Raman Spectroscopy - access the webinar series today Offering significant advantages for bulk, quantitative and non-destructive analysis, Transmission Raman Spectroscopy is a preferred choice for applications where surface analysis is insufficient or prone to errors. Speakers from Agilent, Novartis Pharma, AstraZeneca, Bristol-Myers Squibb and AbbVie go deeper in this FREE webinar series
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Parenteral preparations: formulation challenges Parenteral preparations are defined as solutions, suspensions, emulsions for injection or infusion, powders for injection or infusion, gels for injection and implants. They are sterile preparations that are administrated directly into the systemic circulation of humans or animals
  4. Peak identification by LC/MS: Automation versus analyst High pressure liquid chromatography/mass spectrometry (LC/MS) is an important technique that facilitates the correct and accurate identification of impurities in pharmaceutical products and intermediates
  5. Syncona launches early-stage drug development company, Slingshot Therapeutics The novel early-stage pharmaceutical company aims to collaborate with academic institutions to bring their findings to the clinic, with their first programme centring around inflammatory disease

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Research & Development

Novartis' Leqvio demonstrates LDL cholesterol management potential in Phase III trial

The siRNA can significantly reduce the levels of LDL cholesterol in the blood, reducing the risk of ASCVD in patients
Finance

Calypso enters into agreement to be acquired by Novartis

The acquisition of Calypso gives Novartis full rights to CALY-002, a pipeline-in-a-drug with potential in dermatology, gastrointestinal and rheumatology indications
Research & Development

Intellegens secures $2m to support research of oligonucleotide therapeutic manufacture

In collaboration with CPI, Intellegens has secured a grant from Innovate UK to fund a two year project to augment technology that will assist productivity and yields of oligonucleotide therapeutic manufacture
Manufacturing

Novartis completes acquisition of precision medicine developer Chinook

Novartis has announced the acquisition of a US-based biopharmaceutical company focused on the discovery of precision medicines for kidney diseases named Chinook Therapeutics
Manufacturing

MIT researchers to lead a new centre for continuous mRNA manufacturing

Faculty at the MIT are embarking upon a three-year research programme to design the world's first fully integrated, continuous mRNA manufacturing platform
Drug Delivery

Novartis publishes data on multiple sclerosis treatment

Data showed the sustained efficacy of continuous Kesimpta (ofatumumab) treatment over five years in patients with relapsing forms of multiple sclerosis (RMS)
Research & Development

Novartis and MMV move to Phase III study to treat uncomplicated malaria

As the world faces emerging resistance to current malaria treatments, new medicines are needed to continue the fight toward elimination
Subscribe now